title: An analysis of an inflammatory bowel disease practice in an urban community hospital.
abstract: OBJECTIVE
  To review an individual community gastroenterologist's experience with inflammatory bowel disease (IBD). The aspects studied were distribution of disease, need for hospital admission, immunosuppressants, systemic steroids, and surgery and its indications. The incidence of cancer was also reviewed.
  
  
  METHODS
  The charts of all IBD patients (n=373) seen between 1993 and 1996 by an individual gastroenterologist in an urban community hospital were reviewed for the aforementioned information. Patients seen during this period may have been diagnosed with IBD before or during the period of 1993 to 1996.
  
  
  RESULTS
  Of the 373 patients, 219 had Crohn's disease (CD) and 154 had ulcerative colitis (UC). The most common age of onset for both groups was 20 to 29 years. Distal UC and distal Crohn's colitis patients rarely required surgery, hospitalization, systemic steroids or immunosuppressants. Eighty per cent of patients with small bowel CD and 51% of those with ileocolonic CD required at least one operation. Of the UC patients, 10.4% required surgery. Of the UC patients undergoing surveillance for cancer, none developed cancer but one developed significant dysplasia.
  
  
  CONCLUSIONS
  In both CD and UC the site of the inflammation plays a major role in determining the need for hospitalization, surgery, systemic steroids and immunosuppressants. Distal UC, the most common form of UC in this group of patients, is a very benign disease. Of all forms of IBD, small bowel CD had the greatest need for hospitalization, surgery and systemic steroids.
authors.affiliation: Faculty of Medicine, University of Toronto, Toronto, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Adam
authors.forename: J
authors.initials: J
authors.lastname: Adam
authors.forename: H
authors.initials: H
authors.lastname: Price
mesh_terms: D000328:Adult; D017668:Age of Onset; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002170:Canada; D006760:Hospitalization; D006764:Hospitals, Community; D006786:Hospitals, Urban; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D007414:Intestinal Neoplasms / Q000209:etiology; D012189:Retrospective Studies; D013256:Steroids
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D013256:Steroids